|
12
|
47
|
7rjfA |
Mopd-1 mutant-l47w |
|
101
|
326
|
7p9cA |
Escherichia coli type ii l-asparaginase |
|
40
|
221
|
6zqkB |
Her2-binding scfv-fab fusion 841 |
|
97
|
466
|
6zqkA |
Her2-binding scfv-fab fusion 841 |
|
98
|
326
|
6yziA |
Escherichia coli type ii l-asparaginase |
|
51
|
138
|
6zieA |
Crystal structure of mcl-1 in complex with a neutralizing alphabody cmpx-383b |
|
45
|
108
|
6lu5A |
Crystal structure of bptf-brd with ligand dcbpin5 bound |
|
61
|
152
|
6zieB |
Crystal structure of mcl-1 in complex with a neutralizing alphabody cmpx-383b |
|
42
|
110
|
6lu6A |
Crystal structure of bptf-brd with ligand dcbpin5-2 bound |
|
18
|
114
|
7cgwC |
Complex structure of pd-1 and tislelizumab fab |
|
46
|
214
|
7cgwB |
Complex structure of pd-1 and tislelizumab fab |
|
36
|
218
|
7cgwA |
Complex structure of pd-1 and tislelizumab fab |
|
43
|
223
|
7dunH |
Crystal structure of fab fragment of daratumumab |
|
49
|
212
|
7dunL |
Crystal structure of fab fragment of daratumumab |
|
52
|
214
|
6xukL |
Ablift design 15 of ab 1116ns19.9 |
|
44
|
216
|
6xukH |
Ablift design 15 of ab 1116ns19.9 |
|
50
|
217
|
6xulB |
Apo ab 5b1 |
|
49
|
217
|
6xunB |
Ab 5b1 bound to ca19-9 |
|
51
|
225
|
6xulA |
Apo ab 5b1 |
|
50
|
225
|
6xunA |
Ab 5b1 bound to ca19-9 |
|
109
|
350
|
7cmwA |
Complex structure of parp1 catalytic domain with pamiparib |
|
58
|
258
|
6uy3A |
Structure of anti-hcd33 conditional scfv with methotrexate |
|
60
|
253
|
6uupA |
Structure of anti-hcd33 conditional scfv |
|
44
|
216
|
6xtgH |
Ab 1116ns19.9 bound to ca19-9 |
|
54
|
214
|
6xudL |
Apo ab 1116ns19.9 |
|
45
|
218
|
6xudH |
Apo ab 1116ns19.9 |
|
49
|
214
|
6xtgL |
Ab 1116ns19.9 bound to ca19-9 |
|
166
|
429
|
6kppB |
Bnc105 in complex with tubulin |
|
83
|
380
|
6kppF |
Bnc105 in complex with tubulin |
|
49
|
138
|
6kppE |
Bnc105 in complex with tubulin |
|
166
|
438
|
6kppA |
Bnc105 in complex with tubulin |
|
28
|
127
|
6xxpA |
Crystal structure of nb37, a nanobody targeting prostate specific membrane antigen |
|
28
|
125
|
6xxnA |
Crystal structure of nb7, a nanobody targeting prostate specific membrane antigen |
|
29
|
124
|
6xxnH |
Crystal structure of nb7, a nanobody targeting prostate specific membrane antigen |
|
27
|
127
|
6xxoA |
Crystal structure of nb8, a nanobody targeting prostate specific membrane antigen |
|
29
|
124
|
6xxnG |
Crystal structure of nb7, a nanobody targeting prostate specific membrane antigen |
|
24
|
125
|
6s2iA |
Anti-tumor antibody 14f7-derived scfv in complex with neugc gm3 |
|
2
|
12
|
6n68A |
Nmr solution structure of protonectin (agelaia pallipes pallipes) interacting with sds micelles: an antimicrobial peptide with anticancer activity on breast cancer cells |
|
0
|
6
|
6tggP |
Scfv-1sm3 in complex with glycopeptide containing an sp2-imino sugar |
|
60
|
244
|
6tggH |
Scfv-1sm3 in complex with glycopeptide containing an sp2-imino sugar |
|
163
|
413
|
6veiA |
Crystal structure of human cytosolic isocitrate dehydrogenase (idh1) r132h mutant in complex with nadph and ag-881 (vorasidenib) inhibitor |
|
17
|
93
|
6tktA |
Structure of the bacterial toxin phenomycin |
|
56
|
314
|
6iulA |
Crystal structure of lamprey immune protein |
|
139
|
363
|
6gk0A |
Human dihydroorotate dehydrogenase in complex with class iii histone deacetylase inhibitor |
|
43
|
167
|
6rz3B |
Crystal structure of a complex between the dna-binding domain of p53 and the carboxyl-terminal conserved region of iaspp |
|
49
|
201
|
6rz3A |
Crystal structure of a complex between the dna-binding domain of p53 and the carboxyl-terminal conserved region of iaspp |
|
42
|
108
|
6k04A |
Crystal structure of brd2(bd2)with ligand by27 bound |
|
16
|
81
|
6jzaA |
Structure of fstl1 |
|
36
|
108
|
6k05A |
Crystal structure of brd2(bd1)with ligand by27 bound |
|
0
|
13
|
6oqpA |
U-aitx-ate1 |
